文献速递脊柱关节炎

司库奇尤单抗治疗银屑病关节炎的真实世界6个月和12个月药物留存率、缓解率和应答率:2017例患者、13个欧洲国家

Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2022-04-29

本研究基于欧洲13个国家风湿病质量登记库的真实世界数据,纳入2017例银屑病关节炎患者,评估IL-17抑制剂司库奇尤单抗治疗6个月和12个月的有效性(药物留存、缓解、低疾病活动度和应答率)。结果显示,总体药物留存率6个月为86%、12个月为76%;缓解率和低疾病活动率因评估指标不同而异;b/tsDMARD初治患者的有效性显著更优,且与诊断年限无关,但不同欧洲登记库间存在显著差异。

要点

  • 司库奇尤单抗治疗银屑病关节炎6个月和12个月药物留存率分别为86%和76%。
  • b/tsDMARD初治患者的药物留存、缓解、低疾病活动度和应答率显著优于经治患者。
  • 有效性在不同欧洲国家登记库间存在显著差异,且与诊断年限无关。

核心结论

  • 在大规模真实世界研究中,司库奇尤单抗治疗银屑病关节炎的6个月和12个月有效性与既往肿瘤坏死因子抑制剂的观察性研究相当。

研究设计与样本

  • 基于欧洲13个国家风湿病质量登记库的纵向观察性数据,纳入2017例于2015年至2018年开始司库奇尤单抗治疗的银屑病关节炎患者,采用Kaplan-Meier、log-rank检验、Cox回归及多元线性/逻辑回归分析。

主要发现

  • 总体药物留存率6个月为86%,12个月为76%。
  • 6个月时,基于28关节银屑病关节炎疾病活动指数(DAPSA28)的缓解/低疾病活动度(LDA)率为13%/46%,DAS28-CRP为36%/55%,简化疾病活动指数(SDAI)为13%/56%。
  • 12个月时,基于DAPSA28的缓解/LDA率为11%/46%,DAS28-CRP为39%/56%,SDAI为16%/62%。
  • 6个月时ACR20/50/70应答率分别为34%/19%/11%,12个月时分别为37%/21%/11%。
  • b/tsDMARD初治患者的有效性显著优于经治患者,有效性在不同登记库间差异显著,与诊断年限无关。

关键数值与推荐

  • 缓解/低疾病活动度及ACR应答率的粗率和LUNDEX校正率按DAPSA28、DAS28-CRP、SDAI和CDAI分别报告,数值如原文所述。

临床怎么用

  • 真实世界数据显示司库奇尤单抗在银屑病关节炎中具有较高的药物留存率和一定的缓解/低疾病活动度及应答率,尤其在b/tsDMARD初治患者中效果更佳。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is a lack of real-life studies on interleukin-17 (IL-17) inhibition in psoriatic arthritis (PsA). We assessed real-life 6- and 12-month effectiveness (i.e., retention, remission, low disease activity [LDA], and response rates) of the IL-17 inhibitor secukinumab in PsA patients overall and across 1) number of prior biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), 2) years since diagnosis, and 3) European registries. METHODS: Thirteen quality registries in rheumatology participating in the European Spondyloarthritis Research Collaboration Network provided longitudinal, observational data collected as part of routine care for secondary use. Data were pooled and analyzed with Kaplan-Meier plots, log rank tests, Cox regression, and multiple linear and logistic regression analyses. RESULTS: A total of 2,017 PsA patients started treatment with secukinumab between 2015 and 2018. Overall secukinumab retention rates were 86% and 76% after 6 and 12 months, respectively. Crude (LUNDEX adjusted) 6-month remission/LDA (LDA including remission) rates for the 28-joint Disease Activity Index for Psoriatic Arthritis, the Disease Activity Score in 28 joints using the C-reactive protein level, and the Simplified Disease Activity Index (SDAI) were 13%/46% (11%/39%), 36%/55% (30%/46%), and 13%/56% (11%/47%), and 12-month rates were 11%/46% (7%/31%), 39%/56% (26%/38%), and 16%/62% (10%/41%), respectively. Clinical Disease Activity Index remission/LDA rates were similar to the SDAI rates. Six-month American College of Rheumatology 20%/50%/70% improvement criteria responses were 34%/19%/11% (29%/16%/9%); 12-month rates were 37%/21%/11% (24%/14%/7%). Secukinumab effectiveness was significantly better for b/tsDMARD-naive patients, similar across time since diagnosis (<2/2-4/>4 years), and varied significantly across the European registries. CONCLUSION: In this large real-world study on secukinumab treatment in PsA, 6- and 12-month effectiveness was comparable to that in previous observational studies of tumor necrosis factor inhibitors. Retention, remission, LDA, and response rates were significantly better for b/tsDMARD-naive patients, were independent of time since diagnosis, and varied significantly across the European countries.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Michelsen B, Georgiadis S, Di Giuseppe D, et al. Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. Arthritis Care Res (Hoboken). 2022. PMID: 33460531. doi:10.1002/acr.24560

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。